drugset / Trial / NCT06621017

Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects

NCT06621017 ↗

Phase 2 Completed 40 enrolled Rose Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to assess the efficacy of ROSE-010 on food intake in female subjects with overweight and obesity. The secondary objectives of this study are the following: * To assess the efficacy of ROSE-010 on hunger; * To assess the efficacy of ROSE-010 on satiety; * To assess the efficacy of ROSE-010 on prospective consumption; * To assess the efficacy of ROSE-010 on desire to eat; * To assess the efficacy of ROSE-010 on palatability; * To characterize the pharmacokinetics (PK) of ROSE-010 following subcutaneous (SC) administration on Day 1 and Day 7; and * To evaluate safety and tolerability of SC administrations of ROSE-010 to overweight and obese subjects.

Timeline

Start
2024-09-26
Primary completion
2025-02-27
Completion
2025-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject ROSE-010 Peptide 99 ug Subcutaneous
Subject ROSE-010 Peptide 150 ug Subcutaneous

Indications